New Study Examines Cannabidiol for Nicotine Use Reduction
A recently published study explored the possibility of using cannabidiol (CBD) to reduce symptoms associated with nicotine withdrawal.
Published earlier this month in the journal Cannabis and Cannabinoid Research, the study called “Cannabidiol Reduces Nicotine Withdrawal Severity and State Anxiety During an Acute E-cigarette Abstinence Period: A Novel, Open-Label Study,” tested the addition of cannabidiol (CBD) in nicotine withdrawal efforts (1). Noting the lack of prior research on nicotine use intervention strategies, the study tested the addition of 320mg of CBD administered to 20 daily nicotine users to test the hypothesis that CBD could reduce the intensity of withdrawal symptoms and anxiety (1).
“After controlling for participants' positive CBD expectancies, results were consistent with hypotheses, suggesting CBD reduced both nicotine withdrawal symptom severity and state anxiety during e-cigarette abstinence,” read the results section (1). “Cannabidiol (CBD) has potential to facilitate e-cigarette quit attempts by decreasing withdrawal symptom intensity and anxiety during nicotine e-cigarette abstinence.”
“These preliminary findings suggest testing the impact of CBD on e-cigarette cessation attempts is warranted,” the authors concluded, noting that 8.1 million adults in the US use e-cigarettes (1).
Reference
- Gournay, L. R.; Petry, J.; Bilsky, S.; Hill, M. A.; Feldner, M.; Peters, E.; Bonn-Miller, M.; Leen-Feldner, E. Cannabidiol reduces nicotine withdrawal severity and state anxiety during an acute e-cigarette abstinence period: A novel, open-label study. Cannabis and Cannabinoid Research 2023 DOI: 10.1089/can.2022.0317.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
The Cost of Compliance in the Cannabis Industry
April 1st 2025The financial and reputational risks of non-compliance far outweigh the upfront investment required to establish robust compliance systems. This blog explores the true cost of compliance, what non-compliance can mean for a business, and why investing in compliance is a proactive, strategic decision rather than a burdensome expense.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
